Injectable drug delivery devices market seen reaching $1.67 trillion by 2035

Market Research Future projects the global injectable drug delivery devices market will grow from $868.6 billion in 2026 to $1.665 trillion by 2035, driven by biologics, home-based self-administration and rising chronic disease. The report points to smart injectors, reusable devices and Asia-Pacific demand as key growth themes.

Why it matters: - Injectable delivery devices are becoming core infrastructure for biologics, biosimilars and chronic-disease care. - The shift from hospital-only administration to home use is expanding the addressable market and changing device design priorities. - Rising diabetes, oncology and autoimmune treatment volumes support long-term demand.

What happened: - Market Research Future projects the global Injectable Drug Delivery Devices Market will rise from USD 868.60 billion in 2026 to USD 1,665.30 billion by 2035. - The forecast implies a 7.50% CAGR for 2026 to 2035. - The market base was estimated at USD 808.00 billion in 2025. - The report was published July 21, 2026. - More information is available in the full report.

The details: - The report says growth is being driven by biologics and biosimilars that require parenteral delivery platforms. - Home-based self-administration is creating demand for safer and easier-to-use devices. - The report cites the World Health Organization’s estimate of 830 million adults living with diabetes. - The global insulin-dependent population exceeds 75 million. - GLP-1 adoption for obesity management is supporting diabetes-related device demand. - Immune checkpoint inhibitors are expanding the population needing sustained injectable therapy. - The FDA has recorded 18 novel biological approvals during recent annual tracking cycles. - China’s 14th Five-Year Plan is supporting domestic drug safety and high-quality development. - Canada updated national home-infusion guidelines in 2024. - The UK NHS Long-Term Plan targets a 25% shift of injectable-biologic administration from infusion suites to patient homes by 2028. - AI-enabled smart injectors and connected delivery platforms are emerging as a major product trend. - Start-ups have raised more than USD 800 million for connected-device and adherence-platform technologies since 2023. - Sustainable design and circular manufacturing are gaining attention as regulators push for less single-use medical waste.

Between the lines: - The forecast reflects a structural shift from one-time device purchases toward recurring demand tied to chronic care and long-duration biologic therapy. - Connected injectors could move the market beyond basic delivery hardware into monitoring and adherence tools. - The report’s regional ranking suggests North America still leads on reimbursement depth, while Asia-Pacific is becoming the fastest-growth geography. - Market concentration remains moderate, which leaves room for both large medtech firms and specialized device developers.

What's next: - The report expects advanced device adoption to accelerate as more biologics move into subcutaneous and home-based formats. - Wearable on-body systems, reusable injectors and sensor-embedded platforms are expected to capture more demand through 2035. - The report also points to further growth from biosimilar expansion, connected-device reimbursement and manufacturing localization. - By 2030, the report forecasts precision connected-device theranostics will play a larger role in injectable drug delivery management.

The bottom line: - Injectable drug delivery is shifting from a supporting function to a strategic platform for biologics, chronic care and at-home treatment.